新型口蹄疫疫苗现场试验设计与实施考量
本文基于2017年6月专家咨询,讨论新型口蹄疫疫苗现场研究的最优设计。提出多中心三臂双盲随机对照试验,比较大农场中新型疫苗、常规疫苗与安慰剂,主要结局为单剂接种后六个月内对发病或感染的易感性。
要点
- 推荐多中心三臂双盲随机对照试验设计
- 选择高暴露风险大农场并开展基线研究
- 主要结局为单剂后六个月内发病或感染易感性
核心结论
- 新型口蹄疫疫苗需在现场条件下评估效果,以更好理解现场性能并支持政策决策和商业化可行性。
研究设计与样本
- 2017年6月组织专家咨询,讨论并定义新型口蹄疫疫苗的最优现场研究设计,主要考虑牛,同时讨论猪和小反刍动物的平行策略。
- 提出的最优设计为多中心(即农场)三臂双盲随机对照试验,比较新型疫苗组、常规疫苗组和安慰剂组。
主要发现
- 研究设计需考虑研究点选择及基线研究以了解暴露风险、安慰剂伦理及与常规疫苗的等效性评估、个体随机与整群随机试验的优劣、预防性接种与反应性接种、随机化与盲法方法。
- 理想研究点为高暴露风险地区的大型农场,主要研究结局为单剂接种后六个月观察期内对发病或感染的易感性。
临床怎么用
- 在现场试验中优先采用多中心三臂双盲随机对照试验,纳入常规疫苗和安慰剂对照。
- 选择高暴露风险地区的大型农场作为研究点,并开展基线研究了解暴露风险。
- 以单剂接种后六个月内对发病或感染的易感性作为主要结局指标。
局限性
- 常规攻毒和免疫原性研究有局限性,结果不总能准确预测现场性能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vaccines are commonly used to control Foot-and-Mouth Disease (FMD) in endemic regions and form an important part of contingency plans for FMD-free countries. Conventional FMD vaccines have numerous limitations, and the U.S. government supports the development of next-generation vaccines. In the U.S., vaccine efficacy is typically demonstrated through experimental vaccination and challenge of animals using the World Organization for Animal Health (OIE) standards. Although conventional challenge and immunogenicity studies provide useful information, they have limitations and results do not always accurately predict field performance. Consequently, there is a need to test next-generation vaccines under field conditions to gain a better understanding of field performance to inform policy decisions and support their viability as a commercial product. In June 2017, an expert consultation was organised to discuss and define an optimal field study design for novel FMD vaccines. Cattle were the primary species considered, although parallel strategies for swine and small ruminants were also discussed. Many methodological and logistical considerations in the study design were identified, including: (1) study site selection and the importance of baseline studies to understand exposure risk, (2) ethics of using a placebo and assessing equivalence with conventional vaccines, (3) merits of using individual randomised versus cluster randomised trials, (4) preventive versus reactive vaccination, and (5) methods of randomisation and blinding. The proposed optimal study design was a multicentre (i.e. farm), three-arm, double-blind randomised controlled trial comparing groups receiving the novel vaccine to a conventional vaccine group and a placebo group. Large farms in areas of high exposure risk were identified as ideal study sites, and the primary study outcome was susceptibility to disease or infection, during a six-month observation period, following a single dose of vaccine. This report provides a summary of the important issues to consider when designing a field efficacy study in livestock and proposes a study design that could be utilised for novel FMD vaccines.
引用
- Lyons NA, Knight-Jones TJD, Bartels C, et al. Considerations for design and implementation of vaccine field trials for novel foot-and-mouth disease vaccines. Vaccine. 2019. PMID: 30685245. doi:10.1016/j.vaccine.2018.12.064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。